Our Products

Teva Products


To achieve our vision to become the most indispensable medicines company in the world, Teva develops and supplies healthcare systems worldwide with specialty and generic medicines, active pharmaceutical ingredients (API), OTC products and new therapeutic entities (NTEs). Our portfolio of pharmaceutical products encompasses all major therapeutic areas and dosage forms while focusing on evolving medical, societal and patient needs around the globe.​ ​​​​
​​​

Specialty Products​

Teva develops and manufactures specialty medicines to meet the needs of patients in CNS, pain and respiratory, as well as in the key areas of women’s health, oncology and biologics. We deliver innovative specialty medicine solutions for patients and healthcare providers worldwide through our advanced medicines, devices and services.

Our Specialty Areas

CNSTeva provides a strong portfolio of Central Nervous System (CNS) products including COPAXONE® for the treatment of Multiple Sclerosis (MS), AZILECT® for the treatment of the symptoms of Parkinson's disease and NUVIGIL® for the treatment of sleep disorders.

 

ResipiratoryTeva provides high-quality treatment for people who suffer from respiratory disorders. Our innovative respiratory products improve therapeutic efficiency, increase inhaler utility and effectiveness, and prolong patient’s reactivity to treatment.
Read more about Respiratory Products»

 

CNSTeva's oncology medicines are dedicated to improving the lives of people with cancer through a range of leading products. Our oncology medicines include TREANDA® for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma
Read more about Oncology Products»

 

CNS
Teva develops and markets a diverse portfolio of products that promote women’s health throughout their lives and significantly improve quality of life.


 

CNSTeva offers an effective portfolio of products for the treatment of pain in opioid-tolerant adult patients with cancer, and for relief of muscle spasm in musculoskeletal conditions. We continue to invest in the development of non-opioid alternatives.
Read more about Pain Products»
For further information on​ Teva’s branded products, please refer to your local Teva website​​​​​
 

 Generic Products

 

A global leader in generic pharmaceuticals • US generics market leader, with approximately 20% market share • 850 molecules - the broadest generic portfolio in the industry • 73 billion tablets and capsules, and over 720 million sterile units manufactured in 2012 • 73 pharmaceutical and API production facilities around the world • Over 1.5 million Teva prescriptions are written each day in the US • 1 out of every 6 generic prescriptions in the U.S. is filled with Teva products • 2.7M Teva prescriptions are written in th EU each day • 1,103 generic approvals in Europe, as of December 2012 • Approximately 2,131 marketing authorization applications pending approval in 30 European countries
Read more about Generic Products » ​​​
 

 Generic Q&A

 

Why is Teva a global leader in generic pharmaceuticals?

Since it was founded in 1901, and for over a century, Teva Pharmaceutical Industries Ltd. has been pursuing the same goal: to make high-quality products accessible to more people and more patients around the world. The scale of our operations, our exceptional know-how and our in-depth understanding of the pharmaceutical business made us the world's leading generic pharmaceutical company. Teva is first to bring you the latest drug developments, first to introduce the most advanced dosage forms, first to meet the highest quality standards, and first to offer  the most competitive prices.

1/9

Are generic drugs safe?

A generic drug is bioequivalent to the original innovative drug and meets the same quality standards. The active ingredient, the content, the dosage form and the usage of a generic drug are similar to those of an innovative drug. Generic drugs are essentially the same as the original drug, but are offered at a lower price.

2/9

What does Bioequivalence mean?

Bioequivalence demonstrates a similar profile of behavior of two products in the human body, in terms of the rate and extent of absorption of the active pharmaceutical ingredient from the gastrointestinal (GI) tract to the blood stream. Bioequivalence study is a regulatory requirement and is performed for all generic drugs to ensure their efficiency and the safety.

3/9

How can you make sure that the generic drug is safe, having tried it in only a limited number of patients?

The generic product's active pharmaceutical ingredient (API) is identical to that of the innovative drug, its purity profile is similar and it is found to be bioequivalent; therefore its safety and efficacy are also comparable.

4/9

Why are generic drugs cheaper?

Generic companies are not required to perform lengthy and costly toxicological and clinical studies; therefore, they can offer their products to the public at considerably lower costs.

5/9

Does every drug have a generic equivalent?

As long as a drug is protected by patents, a generic alternative can't be launched. Sometimes a generic version is approved and available in a specific country or countries, while unavailable in others. However, with the growing emphasis on generics, multiple generic versions of an innovative drug are often developed around about the time it becomes "off patent". Nonetheless, in some instances, even after a patent has expired there is no generic alternative. This may happen due to cost considerations, in cases of drugs designed for a limited use or requiring complex manufacturing processes.

6/9

Does the generic drug look the same as its original equivalent?

Sometimes the generic version of a drug may have a different color or shape from its innovative original, but these changes do not affect the drug's attributes.

7/9

Why are generic drugs’ names different from the original drugs' names?

Regulators demand that generic drugs be given a different name from the original drugs, in order to avoid confusion. Typically, the generic name of a drug is based on the name of its API, whereas the names given to original drugs are intended for marketing purposes.

8/9

What are generic drugs?

Generic drugs offer a therapeutic alternative to innovative drugs. They contain the same active ingredients as the original innovative products, and are available in the same strengths and dosage forms as the original.

9/9

 

 OTC Medicines

 

CNSTe​va provides an extensive range of Over the Counter (OTC) medicines though our joint venture with Proctor & Gamble. Our shared portfolio features branded OTC medicines for cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics and skin medications.
 
 
 
​​
 

 NTE Strategy

 
CNS

 

New Therapeutic Entities (NTEs) are known molecules that are formulated, delivered, or used in a novel way to address unmet patient needs. Combining our strengths in specialty and generic products, Teva is the first pharmaceutical leader to enable an industrial-scale pipeline of NTEs. Teva is committed to ensuring a broad and sustained portfolio of these medicines.​








​​

 

 

 TAPI - Teva Active Pharmaceutical Ingredients

 
 
CNS
With more than 75 years of experience, TAPI is one of the leading global suppliers of active pharmaceutical ingredients (APIs).  TAPI offers a broad portfolio of over 300 high-quality APIs to customers worldwide. TAPI specializes in diverse API-related production technologies, including chemical and other synthesis, fermentation, high potency manufacturing and plant extraction.  
​​